dependent-magnetic resonance imaging (BOLD-MRI) was used to quantify changes in renal oxygenation. Tissue expression and distribution of RLN receptor (RXFP1) was determined by qPCR and immunofluorescence. Expression of vasoconstrictor genes was quantified by qPCR array.

**Results** RXFP1 was detected on glomerular podocytes, renal pericytes, and endothelial cells of the renal, segmental and interlobar arteries of cirrhotic rats. In CCl4 cirrhosis, acute i.v. RLN (4µg) induced a 50% increase in RBF after 60 minutes (p < 0.01 vs. placebo, n = 6). BOLD-MRI showed increased tissue oxygenation at the same timepoint in renal cortex and medulla. Extended s.c. RLN induced a 50% increase in RBF after 60 minutes (p < 0.01 vs. placebo, n = 8) and 57% in BDL (p < 0.001 vs. placebo, n = 5) and increased GFR by 138% in CCl4 (p < 0.01 vs. placebo, n = 8) and 105% in BDL (p < 0.05 vs. placebo, n = 5). Mean arterial pressure was unaffected by RLN. L-NAME (250mg/L) orally (p.o.) abrogated the effect of RLN on RBF and GFR. The relative expression of vasoconstrictor genes in the kidney was markedly reduced by RLN treatment.

**Conclusion** RLN increases RBF in experimental cirrhosis. Crucially, RLN also improves renal function and oxygenation but does not induce systemic hypotension even in decompensated disease. The effects of RLN are mediated via augmentation of NO and downregulation of vasoconstrictor genes known to be important in the pathogenesis of HRS. RLN has potential as a treatment for HRS.

**Disclosure of Interest** None Declared.

---

**PWE-147** HUMAN HERPESVIRUS AND ADENOVIRUS UNIQUE GENETIC SEQUENCES DETECTED IN HEPATOCELLULAR CANCER GENOMES

*doi:10.1136/gutjnl-2013-304907.435*

1W Fateen, 2S Berni, 3H Wood, 4U Morgan, 5G Taylor, 6P Quirke. 1Pathology and Tumour Biology; 2Section of Pre-Cancer Genomics; 3Section of Translational Genomics, University of Leeds, Leeds, UK

**Introduction** Hepatitis C virus (HCV) is the most common cause of hepatocellular cancer (HCC) in the western world. HCV is an RNA virus that does not integrate with human DNA and so the oncogenic mechanisms of HCV remain unclear. Next generation sequencing (NGS) provides a flexible platform and generates large amounts of data at a relatively small time and constantly reducing costs. The role of viral infection is well established in the aetiology of wide range of tumours. In this study we investigate DNA of HCV driven HCC for the possibility of integration of all known viral genomes.

**Methods** Bar-coded DNA libraries from 41 samples of various stages of development of HCC from 6 different patients were sequenced in parallel using NGS. One to two million 75bp reads per genome were generated. The reads were aligned to all known viral genomes downloaded from the National Center for Biotechnology Information using Burrows-Wheeler Aligner (BWA). Reads with mapping scores of < 37 were discarded. Basic Local Alignment Search Tool (BLAST) was used to test if the sequences that aligned to viral genomes belonged to the human genome or any other viruses apart from the identified virus. Only those reads were the BWA alignment matched the leading BLAST hit were considered.

**Results** Six test samples mapped to unique sequences from Human herpesvirus 6. The test samples included a single HCC and 5 premalignant nodules from 2 different patients. Six test samples mapped to unique sequences of Human Adenovirus (6/41). The test samples in this case included 4 HCCs and a 2 premalignant nodules from 2 different patients. A single dysplastic nodule mapped to Human papillomavirus.

**Conclusion** DNA from HCV driven HCC was searched for all viral genome sequences only Human Herpes 6, Human Adenovirus and Human papillomavirus were found in a small number of cases.

Further studies are needed to understand their relation to HCV hepatocarcinogenesis.

**Disclosure of Interest** None Declared.

---

**PWE-148** HEPATOTOXICITY FROM ANABOLIC ANDROGENIC STEROIDS MARKETED AS DIETARY SUPPLEMENTS: CONTRIBUTION FROM ABCB11 MUTATIONS?

*doi:10.1136/gutjnl-2013-304907.436*

1Y Elsherrif, 2J R Potts, 3M R Howard, 1A Barnardo, 3S Cairns, 2A S Knisely, 1S Verma. 1Department of Gastroenterology and Hepatology, Brighton and Sussex University Hospitals; 2Department of Medicine, Brighton and Sussex Medical School; 3Department of Pathology, Brighton and Sussex University Hospitals, Brighton; 1Institute of Liver Studies, King’s College Hospitals, London, UK

**Introduction** In the United Kingdom (UK) it is illegal to produce, supply, or possess anabolic androgenic steroids (AAS) with intent. Despite this, non-prescription use of AAS, often marketed as dietary supplements, persists. We encountered drug-induced liver injury (DILI) associated with use of AAS and attempted to elucidate underlying mechanisms.

**Methods** We describe two patients with cholestatic DILI following ingestion of the dietary supplement massdrol (“Celtic Dragon”) containing the AAS 2a-17a-dimethyl-etiocholan-3-one,17b-ol.

**Results** Two Western European males (aged 25 and 45 years) presented to our institute between July, 2011, and March, 2012, with jaundice and intractable pruritus following use of massdrol acquired from fellow gym users. Screening found no other causes of hepatobiliary disease. Despite significant hyperbilirubinaemia (respective peaks: 614 and 229 µmol/L), peak gamma glutamyl transferase activities were within “normal range”. Besides “bland” intractable cholestasis, consistent with DILI, liver biopsy in both found deficiency of canalicular expression of the export enzyme αfetoprotein (CD10), alanyl aminopeptidase (CD13), GGT, and carboxyribozymic antigen (CD66). This suggested generalised abnormality in cholestasis trafficking to, or retention within, canalicular membranes, as seen in ATPB81 disease (familial intrahepatic cholestasis 1 [FIC1]). The younger patient showed normal expression of bile salt export pump (BSEP, encoded by ABCB11) and of multidrug resistance protein 3 (MDR3, encoded by ABCB4); in the older BSEP but not MDR3 marking was focally diminished. While this may have been due to AAS-induced inhibition of expression of normal ATPB81, it also raised the intriguing possibility of mutation in either of these genes – in effect, that AAS exposure had triggered initial episodes of benign recurrent intrahepatic cholestasis type 1/2. On sequencing, ATPB81 was normal in both patients; the younger was heterozygous for the mutation c.2093G>A mutation in ABCB11, a known polymorphism previously encountered in association with intrahepatic cholestasis following antibiotic exposure (personal communication, R Thompson). Morbidity from cholestasis and pruritus was substantial, necessitating use of multiple antipruritic agents and consideration for extracorporal albumin dialysis (MARS). At last follow-up, however, jaundice was resolved in both.

**Conclusion** AAS marketed as dietary supplements remain a cause of serious DILI in the UK; underlying mechanisms remain speculative but may include unmasking of genetic cholestatic syndromes.

**Disclosure of Interest** None Declared.

---

**PWE-149** THE EFFICACY AND SAFETY OF TREATING HEPATITIS C IN PATIENTS WITH A DIAGNOSIS OF SCHIZOPHRENIA

*doi:10.1136/gutjnl-2013-304907.437*

1Z Mustafa, 2J Schofield, 3P R Mills, 1M Priest, 4R Fox, 2S Dutta, 3J Morris, 2E Forrest, 3R Gillespie, 4A J Stanley, 5S Barclay, 6Glasgow Royal Infirmary; 7NHS Greater Glasgow & Clyde; 8Gartnavel General Hospital; 9Victoria Infirmary; 10Southern General Hospital, Glasgow, UK

**Introduction** PATIENTS WITH A DIAGNOSIS OF SCHIZOPHRENIA THE EFFICACY AND SAFETY OF TREATING HEPATITIS C IN THE EFFICACY AND SAFETY OF TREATING HEPATITIS C IN PATIENTS WITH A DIAGNOSIS OF SCHIZOPHRENIA.

**Methods** We describe two patients with cholestatic DILI following ingestion of the dietary supplement massdrol (“Celtic Dragon”) containing the AAS 2a-17a-dimethyl-etiocholan-3-one,17b-ol.

**Results** Two Western European males (aged 25 and 45 years) presented to our institute between July, 2011, and March, 2012, with jaundice and intractable pruritus following use of massdrol acquired from fellow gym users. Screening found no other causes of hepatobiliary disease. Despite significant hyperbilirubinaemia (respective peaks: 614 and 229 µmol/L), peak gamma glutamyl transferase activities were within “normal range”. Besides “bland” intractable cholestasis, consistent with DILI, liver biopsy in both found deficiency of canalicular expression of the export enzyme αfetoprotein (CD10), alanyl aminopeptidase (CD13), GGT, and carboxyribozymic antigen (CD66). This suggested generalised abnormality in cholestasis trafficking to, or retention within, canalicular membranes, as seen in ATPB81 disease (familial intrahepatic cholestasis 1 [FIC1]). The younger patient showed normal expression of bile salt export pump (BSEP, encoded by ABCB11) and of multidrug resistance protein 3 (MDR3, encoded by ABCB4); in the older BSEP but not MDR3 marking was focally diminished. While this may have been due to AAS-induced inhibition of expression of normal ATPB81, it also raised the intriguing possibility of mutation in either of these genes – in effect, that AAS exposure had triggered initial episodes of benign recurrent intrahepatic cholestasis type 1/2. On sequencing, ATPB81 was normal in both patients; the younger was heterozygous for the mutation c.2093G>A mutation in ABCB11, a known polymorphism previously encountered in association with intrahepatic cholestasis following antibiotic exposure (personal communication, R Thompson). Morbidity from cholestasis and pruritus was substantial, necessitating use of multiple antipruritic agents and consideration for extracorporal albumin dialysis (MARS). At last follow-up, however, jaundice was resolved in both.

**Conclusion** AAS marketed as dietary supplements remain a cause of serious DILI in the UK; underlying mechanisms remain speculative but may include unmasking of genetic cholestatic syndromes.

**Disclosure of Interest** None Declared.
Introduction   Treating hepatitis C with pegylated interferon alpha may induce or exacerbate psychiatric illness including depression, mania and aggressive behaviour. There is limited data regarding treatment in the context of chronic schizophrenia. We sought to establish the safety and efficacy of treatment of patients with a diagnosis of schizophrenia amongst patients attending treatment centres in Greater Glasgow.

Methods   Patient and treatment data collected on the Scottish hepatitis C database were retrospectively analysed according to the presence or absence of a diagnosis of schizophrenia. Combination antiviral therapy was defined as Interferon (pegylated or standard) and Ribavirin. Treatment outcomes including sustained viral response (SVR) rates, reasons for treatment termination and adverse events were documented.

Results   5497 patients were recorded on the database, of whom 64 (1.2%) had a diagnosis of schizophrenia. Patients with and without schizophrenia were of similar age at diagnosis [median 34 (IQR 31–40) vs 36 (IQR 29–41) years, p = 0.85]. Patients with schizophrenia had higher rates of current or previous intravenous drug use [50/64 (78.1%) vs 3015/5433 (55.5%), p < 0.01] and prior alcohol excess > 21 units/week [25/64 (39%) vs 1211/5433 (22.2%), p = 0.02]. More patients with schizophrenia had a diagnosis of cirrhosis [15/64 (20.3%) vs 589/5419 (10.86%), p = 0.02]. Of those patients who had attended at least one clinic appointment 1639/4415 (37.1%) of patients without schizophrenia commenced treatment versus 26/61 (42.6%) of patients with schizophrenia (p = 0.21). Patients with schizophrenia took almost three times as long to commence treatment after initial referral [median 1123 (IQR 531–2130) vs 421 (IQR 209–1086) days, p < 0.01], despite similar times from referral to first attendance [median 65 (IQR 36–141) vs 62 (IQR 35–130) days, p = 0.92]. The treatment outcomes were as follows:

Conclusion   Patients with stable schizophrenia are good candidates for hepatitis C treatment.

Disclosure of Interest   None Declared.

Neoplasia and cancer pathogenesis

PWE-150   “THE EARLY GROWTH RESPONSE GENES INDUCE APOPTOSIS IN COLON CANCER CELLS”

doi:10.1136/gutjnl-2013-304907.438

1^A Koulouris. 2Gastroenterology-Experimental Immunology, Queen Mary, University of London, London, UK

Introduction   The Egr family (Early Growth Respon Genes) of zinc finger transcription factors, which consists of four members: Egr-1, -2, -3 and -4, have been proved to have dynamic functions in the regulation of cell growth and the immune responses. Moreover, in a number of malignancies—which is a cell growth and immune related process— it seems that Egr1 and 2 induce apoptosis leading to the inhibition of the tumour growth. The present study was designed to answer the question whether colon cancer cells undergo apoptosis when the EGR genes are exogenously introduced and if the presence of a mutant p53 can affect this apoptotic pathway.

Methods   Two cell lines deriving from human colon cancer, one p53 negative (DLD1) and another p53 positive (HCT116) were transfected with Egr-1, -2 and -3 and a fluorescent protein which was the marker of the transfection. The transfected cells were incubated for 48 hours. Flow cytometry was used to create a pure population of transfected cells and 24 hours later these cells were examined in the fluorescent microscope and compared with the controls.

Results   We found that all three Egr members can suppress tumour cell growth suggesting that the function of Egr in the control of cell growth is not associated with the function of p53. In addition to the growth arrest, the transfected cells changed morphology to round shape indicating of senescence.

Conclusion   This may suggest that Egr molecules are important to control the unwanted growth in response to malignant transformation. Our results not only demonstrated an important function of Egr molecules and also indicate the therapeutic potential for the treatment of tumour.

Disclosure of Interest   None Declared.

PWE-151   CELL-MEDIATED IMMUNE RECOGNITION OF CEA IS ASSOCIATED WITH EARLY TUMOUR RECURRENCE FOLLOWING RESECTION OF COLORECTAL CANCER

doi:10.1136/gutjnl-2013-304907.439

1^C Brown, 1M Scurr, 1G Betts, 1A Gallimore, 1,*A Godkin. 2Institute of Infection and Immunity, Cardiff University, Cardiff; 2Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK

Introduction   Colorectal cancer (CRC) is one of the commonest malignancies in men and women. Clinical staging is used to predict prognosis after resection. The interaction of the cancer with the adaptive cellular immune response plays an important role in disease pathogenesis, but this relationship may be compromised by a population of regulatory Foxp3+ CD4+ T cells (Treg). Here, the 5-year post-operative clinical outcome was correlated with pre-operatively measured anti-tumour immune responses.

Methods   Eighty patients with non-metastatic CRC, undergoing a resection with curative intent, were recruited over 24 months. CD4+ T cell responses to tumour associated antigens (CEA and ST4) were compared to control antigens (PPD and HA). The influence of immune regulation was measured by repeating the assays after in vitro depletion of Tregs. Clinical databases were interrogated for details, including morbidity and mortality data, and the five year overall survival (OS), time to progression (TTP), and progression free survival (PFS) was calculated. These parameters were compared to the original details of pre-operative anti-tumour immune responses.